Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against CYTRX CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- CYTR

GlobeNewswire March 17, 2014

CytRx Establishes Research and Development Team and Opens New Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform

Business Wire March 17, 2014

EQUITY ALERT: The Rosen Law Firm Files Securities Fraud Class Action Against CytRx Corporation and Its Stock Promotion Firms -- CYTR

GlobeNewswire March 15, 2014

Harwood Feffer LLP Announces Investigation of CytRx Corporation

PR Newswire March 14, 2014

SHAREHOLDER ALERT: Investigation of CytRx Corporation Announced by Law Offices of Howard G. Smith

Business Wire March 13, 2014

The Rosen Law Firm Announces Investigation of Securities Claims Against CytRx Corporation - CYTR

Business Wire March 13, 2014

CytRx Reports 2013 Financial Results

Business Wire March 5, 2014

Catasys Announces Transition to a New Board of Directors

PR Newswire February 13, 2014

CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire February 5, 2014

CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York City

Business Wire February 3, 2014

CytRx Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Business Wire January 31, 2014

CytRx Announces Proposed Public Offering of Common Stock

Business Wire January 30, 2014

CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma

Business Wire January 23, 2014

CytRx Receives FDA Approval to Extend Aldoxorubicin Dosing Cycles until Disease Progression in Upcoming Pivotal, Global Phase 3 Trial for Soft Tissue Sarcomas

Business Wire January 21, 2014

MissionIR Interview With CytRx Embellishes on Clinical Trial Results and Plans for an Incredible 2014

Marketwired January 16, 2014

CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development

Business Wire January 16, 2014

CytRx Corporation Doses First Patient in Phase 2 Clinical Trial with Aldoxorubicin for the Treatment of Unresectable Glioblastoma Multiforme (Brain Cancer)

Business Wire January 14, 2014

CytRx Reports Additional Analyses Supporting Highly Statistically Significant Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas

Business Wire January 8, 2014

TrendingWallStreet.com Starts Volume Coverage on HLT, CYTR, MDDD, and PVCT

Accesswire December 13, 2013

Five Star Equities Issues New Research Reports on AVNR, BGMD, CYTR and ECTE

Accesswire December 12, 2013